文献速递冠心病外科

丙泊酚强化停搏液的心肌保护作用:多中心盲法三组随机试验

Propofol-supplemented cardioplegia: A multicenter blinded 3-group randomized trial (Propofol for Myocardial Protection Trial 2: ProMPT2).
PubMed 文献 · J Thorac Cardiovasc Surg · 2025-10-02

该多中心盲法随机对照试验在英國3家医院纳入240例首次接受体外循环冠状动脉旁路移植术的成人,比较停搏液中加入高剂量丙泊酚(12 μg/mL)、低剂量丙泊酚(6 μg/mL)与安慰剂的安全性及疗效。主要结局为术后48小时内肌钙蛋白T释放,结果显示两种剂量均安全但均无心肌保护证据。

要点

  • 停搏液中加入丙泊酚高剂量或低剂量均安全,但无心肌保护证据。
  • 术后48小时肌钙蛋白T释放三组间无显著差异。
  • 不良事件及死亡数三组间未见明显安全性信号。

核心结论

  • 在温血停搏液中加入丙泊酚(6 μg/mL或12 μg/mL)是安全的,但无证据表明任一剂量具有心肌保护作用。

研究设计与样本

  • 英国3家医院开展的双盲、平行组随机对照试验,共纳入240例首次接受体外循环冠状动脉旁路移植术的成人。
  • 参与者随机分配至高剂量丙泊酚组(78例,浓度12 μg/mL)、低剂量丙泊酚组(80例,浓度6 μg/mL)或安慰剂组(82例,生理盐水)。
  • 主要结局为术后48小时内肌钙蛋白T测量值,随访12个月。

主要发现

  • 48小时肌钙蛋白T释放几何均值(95%CI)在高剂量组为145 ng/L(125-168),低剂量组为162 ng/L(138-191),安慰剂组为150 ng/L(125-180)。
  • 延长住院或危及生命的不良事件共96例(高剂量组33例、低剂量组26例、安慰剂组37例),死亡4例(低剂量组1例、安慰剂组3例)。

临床怎么用

  • 基于本试验结果,不推荐在温血停搏液中常规添加丙泊酚以期望心肌保护获益。
  • 丙泊酚强化停搏液在此剂量范围内安全性可接受,但需权衡缺乏疗效证据。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Coronary artery bypass grafting using cardiopulmonary bypass and cardioplegic arrest is an effective treatment for coronary artery disease. Research suggests supplementing the cardioplegia solution with propofol may be cardioprotective. Our aim was to compare the safety and efficacy of supplementing the cardioplegia solution with different doses of propofol in adults undergoing first-time surgery. METHODS: A blinded, parallel group randomized controlled trial conducted in 3 hospitals in the United Kingdom compared a cardioplegia solution supplemented with high-dose propofol (concentration 12 μg/mL), low-dose propofol (concentration 6 μg/mL), and placebo (saline). Primary outcome was cardiac troponin T measurements over the first 48 hours after surgery. Participants were followed for 12 months. RESULTS: In total, 240 participants, median age 66 years, 90% male, were randomly allocated: 78 to high-dose propofol, 80 to low-dose propofol, and 82 to placebo. In total, 239 participants were included in the primary analysis. Geometric mean cardiac troponin release at 48 hours (95% confidence interval) was 145 ng/L (125-168), 162 ng/L (138-191), and 150 ng/L (125-180) in the high-dose propofol, low-dose propofol, and placebo groups, respectively (adjusted geometric mean ratio 1.06; 95% confidence interval, 0.97-1.15; P = .20, for pairwise comparisons between high- and low-dose propofol and between low-dose propofol and placebo). A total of 96 adverse events that prolonged the hospital stay or were life-threatening were reported (33, 26, and 37 in the high-dose propofol, low-dose propofol, and placebo groups, respectively), as well as 4 deaths (1 low-dose propofol group, 3 placebo group). CONCLUSIONS: Propofol supplementation of warm blood cardioplegia at both the lower and higher concentrations is safe, but there is no evidence to suggest either dose is cardioprotective.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Angelini GD, Smartt HJM, Joyce K, et al. Propofol-supplemented cardioplegia: A multicenter blinded 3-group randomized trial (Propofol for Myocardial Protection Trial 2: ProMPT2). J Thorac Cardiovasc Surg. 2025. PMID: 41046123. doi:10.1016/j.jtcvs.2025.09.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。